MIM
NBTX

Monashee Investment Management’s Nanobiotix NBTX Stock Holding History

Monashee Investment Management’s Portfolio NBTX Stock Details NBTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,000
Closed -$248K – 411
2020
Q4 		$248K Buy
+15,000
New +$258K 0.03% 214

Other funds holding NBTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Monashee Investment Management's NBTX Position: Q1 2021 in Review

Monashee Investment Management sold out of Nanobiotix (NBTX) in Q1 2021, closing a stake of 15,000 shares — an estimated $248K sold.

Monashee Investment Management first reported a position in NBTX in Q4 2020 and held it in 1 quarter. The position peaked at $248K in Q4 2020. 10 funds tracked by Wall St. Rank hold NBTX as of Q1 2021.

  • Monashee Investment Management reported no remaining Nanobiotix position as of Q1 2021 after selling out during the quarter.
  • Monashee Investment Management sold 15,000 Nanobiotix shares in Q1 2021, an estimated $248K.
  • Monashee Investment Management first reported a position in Nanobiotix in Q4 2020 and held it in 1 quarter.
  • Monashee Investment Management's Nanobiotix position peaked at $248K in Q4 2020.
  • 10 funds tracked by Wall St. Rank held Nanobiotix as of Q1 2021.

Based on Monashee Investment Management's 13F filing for Q1 2021, filed 14 May 2021.